Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021, with a specific transaction date of April 13, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Instrument | Transaction Type | Price per Share | Total Volume (Shares) | Exchange |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition under Share Reward Plan | £12.906 | 180 (Aggregated across 10 individuals) | London Stock Exchange (XLON) |
Material Changes
The filing does not provide comparative data against prior periods. It reports initial notifications of share acquisitions for the specified date only.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of routine executive share plan transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership and matching shares.
- Participants: Transactions involved 10 senior executives, including the CEO (Ms E Walmsley), President of Global Vaccines (Mr R Connor), and CEO of ViiV Healthcare (Ms D Waterhouse).
- Volume Details: Most executives acquired 18 shares (9 partnership + 9 matching), while three individuals (Mr D Jackson, Mr R Simard, Mr P Thomson, Ms D Waterhouse) acquired 20 shares (10 partnership + 10 matching).
- Market Price: The uniform transaction price was £12.906 per share.
- Financial Data Absence: Investors should note that this filing provides no insight into GSK's operational performance, financial health, or strategic outlook for the period.